Current version snapshot
Current · version 3: Cagrilintide↗
Related names recorded in this version: AM833, CagriSema↗↗
An experimental long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema. FDA says it is not an approved drug and cannot be used in compounding.↗↗↗
The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that cagrilintide cannot be used in compounding. 234
What this version reported
A published Phase 2 trial of cagrilintide alone and large Phase 3 trials of the cagrilintide-semaglutide combination report weight loss; combination results cannot be credited to cagrilintide alone. FDA states that cagrilintide has not been found safe and effective for any condition.↗↗↗
Trial records: NCT07253285
Reader guide in this version
Key takeaway
Cagrilintide is an experimental, long-acting version of amylin, a pancreatic hormone that promotes fullness, developed by Novo Nordisk for weight management.1,3 It is not an approved drug. FDA states that cagrilintide is not a component of any FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.2 A 706-person Phase 2 trial reported more weight loss with cagrilintide than with placebo. The later large trials in our human evidence review test it combined with semaglutide, a combination known as CagriSema, so their results cannot be credited to cagrilintide alone.3,4
At a glance
- What it is
- An investigational long-acting amylin analogue from Novo Nordisk, also known as AM833.1,3
- FDA status
- Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.2
- Human evidence
- One published Phase 2 trial of cagrilintide alone and large Phase 3 trials of the cagrilintide-semaglutide combination. Phase 3 trials of cagrilintide alone are registered.3,4,5
- Evidence strength
- Large randomized human trials
What is cagrilintide?
Cagrilintide is an experimental peptide being developed by Novo Nordisk, which ClinicalTrials.gov lists as the sponsor of the trial record cited on this profile.1
The Phase 2 trial report describes natural amylin as a pancreatic hormone that induces a feeling of fullness, and cagrilintide as a long-acting amylin analogue under investigation for weight management.3
It is also studied in combination with semaglutide; that combination is known as CagriSema.1,4
How is cagrilintide thought to work?
Cagrilintide is designed to mimic amylin, which the Phase 2 report describes as a hormone that induces satiety.3
The sources reviewed here do not establish how much cagrilintide contributes to the effects reported for the cagrilintide-semaglutide combination.4
What do human studies show?
In the Phase 2 trial, 706 adults without diabetes who had obesity, or overweight with high blood pressure or abnormal blood fats, were randomized across 57 sites in ten countries. Over 26 weeks, average weight loss ranged from 6.0% to 10.8% across the cagrilintide groups, compared with 3.0% with placebo.3
Gastrointestinal events occurred more often in the cagrilintide groups than with placebo. The trial was funded by its sponsor and was not designed to assess long-term outcomes.3
In REDEFINE 1, 3,417 adults with overweight or obesity and no diabetes were randomized. Average weight change at 68 weeks was −20.4% with the cagrilintide-semaglutide combination and −3.0% with placebo, and gastrointestinal adverse events occurred in 79.6% and 39.9%, respectively.4
Those combination results cannot be attributed to cagrilintide alone, and the trial abstract does not report the cagrilintide-alone comparison needed to judge each component’s contribution.4
What the evidence base contains
- Large randomized human trial A 26-week randomized Phase 2 trial comparing several cagrilintide groups in 706 adults without diabetes, with placebo and liraglutide comparison groups, published in The Lancet.3
- Large randomized human trial REDEFINE 1, a 68-week randomized Phase 3a trial in 3,417 adults with overweight or obesity that compared the cagrilintide-semaglutide combination with each component alone and with placebo, published in The New England Journal of Medicine.4
- Registered trial without results A Phase 3 trial of cagrilintide alone in people with overweight or obesity and type 2 diabetes (NCT07220759), listed as active, not recruiting in its August 3, 2026 registry record.5
- Registered trial without results A Phase 3 trial of cagrilintide alone in overweight or obesity (NCT07745504), listed as not yet recruiting in its August 4, 2026 registry record.6
Evidence-strength label: Large randomized human trials. How this label is assigned
Is cagrilintide FDA-approved?
No. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, states that cagrilintide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.2
The same page states that retatrutide and cagrilintide cannot be used in compounding under federal law.2
Cagrilintide remains in clinical trials, including Phase 3 trials registered by Novo Nordisk. None of the sources reviewed here reports an approval of cagrilintide or the CagriSema combination in any country.1,2,5
Timeline
- Results of the Phase 2 cagrilintide trial are published in The Lancet.3
- REDEFINE 1 results for the cagrilintide-semaglutide combination are published in The New England Journal of Medicine.4
- FDA’s page on unapproved GLP-1 drugs, which says cagrilintide cannot be used in compounding, is updated, as shown by its content-current date.2
What is still unknown?
Whether cagrilintide alone produces lasting weight loss and benefits over longer periods: the only published trial of cagrilintide alone cited here lasted 26 weeks.3
How much cagrilintide adds to semaglutide in the combination, which the REDEFINE 1 abstract does not report.4
Its effects in children and adolescents, which a registered Novo Nordisk trial is studying.1
What is in cagrilintide products marketed outside clinical trials, which FDA says cannot be used in compounding and have not been found safe and effective.2
Sources for this version
- 1Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial (2021) · PMID 34798060 ↗
The Lancet · Official source · Source checked November 14, 2026
- 4Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, 2025) · PMID 40544433 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 5ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 6ClinicalTrials.gov record NCT07745504 · retained source version 2026-08-04:624035118e08abe47d4c56faae694b0047f077f295c17f9043520d41dcfc3f70 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026